Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iberdomide Maintenance After ASCT in Newly Diagnosed Multiple Myeloma
NCT04564703Phase 2Active, not recruiting
- Start
- Feb 2021
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label trial of iberdomide in multiple myeloma (MM) (3 cohorts). Primary endpoints: Rate of improvement in response at 6 months and Rate of dose reductions/discontinuations at 6 months. Started Feb 2021; status: active, not recruiting.
02
Drugs
iberdomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04564703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04564703.